Inclusion Criteria:

- Subjects with CD20 positive aggressive non-Hodgkin's lymphoma (NHL) including DLBCL,
transformed follicular lymphoma (FL) & grade 3b FL.

Refractory to, or relapsed following, first-line treatment with rituximab combined with
anthracycline- or anthracenedione-based chemotherapy as defined by the protocol.

- Computed tomography (CT) with involvement of 2 or more clearly demarcated lesions
with a long axis > 1.5 centimeters (cm) and short axis ≥ 1.0 cm or 1 clearly
demarcated lesion with a long axis >2.0 cm and short axis ≥1.0 cm.

- Baseline [18F] fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans must
demonstrate positive lesions compatible with CT defined anatomical tumor sites.

- Age 18 yrs or older.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

- Eligible for high dose chemotherapy and autologous stem cell transplant (ASCT).

- Resolution of toxicities from first-line therapy to a grade that in the opinion of
the investigator does not contraindicate study participation.

- Signed written informed consent.

Exclusion Criteria:

- Previous cancer therapy for lymphoma, with the exception of required rituximab/
anthracycline- or anthracenedione-based chemotherapy, monotherapy rituximab prior to
first-line therapy and / or as a maintenance therapy, or limited field radiotherapy
(as defined by the protocol).

- Any anti-cancer therapy, except limited field radiotherapy, within 2 weeks prior to
start of study therapy.

- Chronic Glucocorticoid use (limited acute use is allowed and defined by the
protocol).

- History of significant cerebrovascular disease.

- Abnormal/ inadequate white blood cell (WBC) count, liver, and kidney function.

- Clinically significant cardiac disease, active or chronic infections, serious
significant diseases, other cancer within last 5 years.

- Known or suspected hypersensitivity to study treatments.

- Prior treatment with anti-CD20 monoclonal antibodies, at any time, or treated with
other monoclonal antibodies within 3 months prior to start of study therapy, with the
exception of rituximab in both instances.

- Inability to comply with the protocol activities.

- Pregnant or lactating women or female patients of child-bearing potential (or male
patients with such partners) not willing to use adequate contraception during and up
to 1 year following dosing completion.